ABT.NEO Abbott Labs CDR (CAD Hedged)
- Market cap
- CAD 244B
- P/E
- 13.1x
- P/B
- 3.38x
- ROE
- 8.3%
- Dividend yield
- 1.58%
- Fundamental score
- 2.0/5
Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Mar 2026.
Is ABT.NEO undervalued?
Graham numberABT.NEO trades 40.4% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Abbott Labs CDR (CAD Hedged) fundamental analysis
11 of 22 checks passedROE 0/2
Low return on equity (8.3%), below 10%.
ROA 1/1
Return on assets (3.9%) is above the industry median (-7.4%).
Profit Consistency 1/2
Profitable for 4 consecutive years.
Earnings Growth 5Y 0/1
Earnings per share history is shorter than 5 years.
Earnings Acceleration 0/1
Not enough positive earnings history to compare last year's growth with the 5-year average.
Earnings Growth vs Industry 0/1
Last year's EPS growth (-51.5%) is below the industry median (5.2%).
Revenue Growth 1/2
Revenue grew 0.5% a year over the past 3 years.
Short-term Liquidity 1/1
Current assets cover short-term liabilities.
Long-term Liabilities 0/1
Current assets do not cover long-term liabilities.
Debt to Equity 1/2
Moderate debt to equity (56.9%), up to 100%.
Debt Trend 0/1
Debt to equity history is shorter than 5 years.
Debt Coverage 0/1
Operating cash flow does not cover 20% of total debt.
Interest Coverage 1/1
EBIT is 9.3x against interest expense, well covered.
PE vs Market 1/1
PE (12.9x) is below the market median (20.3x).
PE vs Industry 1/1
PE (12.9x) is below the industry median (19.0x).
PBV 0/1
Price to book (3.3x) is above the industry median (2.5x).
Graham Number 0/1
The price is above the Graham number (PE x PB = 43.0, limit 22.5).
PEG 0/1
PEG needs positive PE and positive 5-year earnings growth.
Dividend Yield 1/2
Dividend yield (4.9%) is above the bottom 25% of dividend payers in the market.
Dividend Stability 1/2
Dividends paid without a cut of more than 10% for 5 years.
Dividend Growth 0/1
Dividends paid did not grow over the past 5 years.
Payout Ratio 1/1
Payout ratio is 63.1%, covered by earnings.
Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score
Abbott Labs CDR (CAD Hedged) stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Abbott Labs CDR (CAD Hedged)
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, h…
Full company profileAbbott Labs CDR (CAD Hedged) financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 1 quarter up to Mar 31, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Abbott Labs CDR (CAD Hedged) annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | 43.7B | 40.1B | 42.0B | 44.3B | 44.7B |
| Gross Profit | 24.5B | 22.1B | 23.2B | 25.0B | 25.1B |
| Operating Income | 8.36B | 6.48B | 6.83B | 8.05B | 5.38B |
| EBITDA | 12.1B | 10.5B | 10.8B | 12.1B | 9.70B |
| Net Income | 6.93B | 5.72B | 13.4B | 6.52B | 4.31B |
| EPS | 3.99 | 3.30 | 7.74 | 3.76 | 2.47 |
| Balance Sheet | |||||
| Total Assets | 74.4B | 73.2B | 81.4B | 86.7B | 110B |
| Total Liabilities | 37.5B | 34.4B | 33.5B | 33.9B | 57.7B |
| Shareholders' Equity | 36.7B | 38.6B | 47.7B | 52.1B | 52.1B |
| Cash & Short-term Investments | 9.88B | 6.90B | 7.62B | 8.52B | 6.80B |
| Cash Flow | |||||
| Operating Cash Flow | 9.58B | 7.26B | 8.56B | 9.57B | 5.26B |
| Capital Expenditure | 1.78B | 2.20B | 2.21B | 2.17B | 1.60B |
| Free Cash Flow | 7.80B | 5.06B | 6.35B | 7.40B | 3.66B |
| Ratios | |||||
| ROE | 18.9% | 14.8% | 28.1% | 12.5% | 8.3% |
| ROA | 9.3% | 7.8% | 16.5% | 7.5% | 3.9% |
| Net Profit Margin | 15.9% | 14.3% | 31.9% | 14.7% | 9.6% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Abbott Labs CDR (CAD Hedged) dividends
- Dividend yield
- 1.58%
- Forward dividend
- -
- Payout ratio
- 63.1%
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | USD 4.12B | 2.37 | 63.1% |
| 2024 | USD 3.84B | 2.22 | 28.6% |
| 2023 | USD 3.56B | 2.05 | 62.1% |
| 2022 | USD 3.31B | 1.90 | 47.7% |
| 2021 | USD 3.20B | 1.82 | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Abbott Labs CDR (CAD Hedged)
Ownership data of Abbott Labs CDR (CAD Hedged) is not available yet.
Abbott Labs CDR (CAD Hedged) company profile
- Company name
- Abbott Labs CDR (CAD Hedged)
- Ticker
- ABT.NEO
- Exchange
- NEO Exchange
- Sector
- Healthcare
- Industry
- Medical Devices
- Employees
- 114,000
- Fiscal year end
- December
- Address
- 100 Abbott Park Road, North Chicago, IL, United States, 60064-6400
- Phone
- 224 667 6100
- Website
- abbott.com
About Abbott Labs CDR (CAD Hedged)
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, hypertriglyceridemia, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. It also offers laboratory and transfusion medicine systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion serology testing; molecular diagnostics polymerase chain reaction instrument systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and measure infectious agents; point of care systems; cartridges for testing blood gas, chemistry, electrolytes, coagulation, and immunoassay; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; and drug and alcohol test. In addition, the company provides pediatric and adult nutritional products and infant formula; rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; diabetes care products, such as glucose and blood glucose monitoring systems; and neuromodulation devices for the management of chronic pain and movement disorders. Abbott Laboratories was founded in 1888 and is based in North Chicago, Illinois.
Abbott Labs CDR (CAD Hedged) management
10- Mr. Robert B. FordChairman of the Board, President & CEO · born 1974
- Mr. Philip P. BoudreauCFO & Executive VP of Finance · born 1973
- Mr. Hubert L. Allen J.D.Executive VP, General Counsel & Secretary · born 1966
- Mr. Daniel Gesua Sive SalvadoriExecutive VP and Group President of Established Pharmaceuticals & Nutritional Products · born 1979
- Ms. Lisa D. EarnhardtExecutive VP & Group President of Medical Devices · born 1970
- Ms. Sabina EwingSenior VP of Business & Technology Services and Chief Information Officer · born 1974
- Mr. Michael ComillaVice President of Investor Relations.
- Erica L. BattagliaVP and Chief Ethics & Compliance Officer
- Ms. Mary K. MorelandExecutive Vice President of Human Resources · born 1966
- Ms. Melissa BrotzSenior Vice President of Global Marketing & External Affairs